Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Our Sustainability Commitment
Our Sustainability Commitment
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2016
IR News
2016 IR News
RSS
IR News
12.16.2016
Notice of Change in Significant Shareholder
12.14.2016
Notice of Cancellation of Treasury Shares
11.28.2016
Santen Announces Phase III SAKURA Program Topline Results in Patients with Non-Infectious Uveitis of the Posterior Segment
11.24.2016
Santen Announces Completion of Share Repurchase Program
11.02.2016
Santen Reports the 2nd Quarter Fiscal 2016 Consolidated Performance
11.01.2016
Santen Announces Status of Repurchase of Own Shares
10.06.2016
Santen, RIKEN and FBRI Announce Research Collaboration to Develop New Retinal Disease Treatments
10.03.2016
Personnel Changes of Corporate Officer
10.03.2016
Santen Announces Status of Repurchase of Own Shares
09.12.2016
Santen Announces Repurchase of Own Shares
09.01.2016
Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)
08.30.2016
Santen Announces the Completion of Establishment Procedures for Chongqing Santen Kerui Pharmaceutical Co., Ltd.
08.22.2016
Santen Completes Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
08.03.2016
Santen and University College London to collaborate on ophthalmic research and education
08.02.2016
Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration
08.02.2016
Santen Reports the 1st Quarter Fiscal 2016 Consolidated Performance
07.19.2016
Santen to Acquire InnFocus, Developer of MicroShunt Glaucoma Implant Device
07.14.2016
Corporate Governance Report
07.04.2016
Santen Receives Positive Recommendation from CDSCO for Sirolimus
05.12.2016
Vekacia® (Ciclosporin 1mg/mL Eye Drops) Pivotal Trial Meets Primary and Key Secondary Endpoints
05.11.2016
Notice of Board of Directors and Corporate Auditor Nominations
05.11.2016
Santen Provides Update on EU Marketing Authorization Application for DE-109 (Sirolimus)
05.11.2016
Flash Report on FY2015 Financial Results
03.30.2016
Santen Enters Licensing Agreement with Ono for FP/EP3 Dual Agonist, ONO-9054
03.22.2016
Santen China and Chongqing Kerui Announce Collaboration to Develop New Ophthalmic Joint Venture
03.10.2016
Notice of Corporate Officer Appointments
02.23.2016
Santen Announces Proposed Dividend Change
02.23.2016
Santen Announces Proposed Dividend Change
02.10.2016
Notice on the Establishment of Santen Business Services Co., Ltd.
02.10.2016
Notice on the Establishment of Santen Business Services Co., Ltd.
02.02.2016
Flash Report on the 3rd Quarter of FY2015 Financial Results
01.18.2016
"Specialized in Ophthalmology" Santen Presents at J.P. Morgan Conference
01.12.2016
Corporate Governance Report
News Archive
